<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS: We previously reported that <z:chebi fb="1" ids="50694">minocycline</z:chebi> attenuates <z:hpo ids='HP_0011009'>acute</z:hpo> brain injury and <z:mp ids='MP_0001845'>inflammation</z:mp> after focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>, and this is partly mediated by inhibition of 5-lipoxygenase (5-LOX) expression </plain></SENT>
<SENT sid="1" pm="."><plain>Here, we determined the protective effect of <z:chebi fb="1" ids="50694">minocycline</z:chebi> on <z:hpo ids='HP_0011010'>chronic</z:hpo> ischemic brain injury and its relation with the inhibition of 5-LOX expression after focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>MAIN METHODS: Focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> was induced by 90 min of middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> followed by reperfusion for 36 days </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="1" ids="50694">Minocycline</z:chebi> (45 mg/kg) was administered intraperitoneally 2h and 12h after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> and then every 12h for 5 days </plain></SENT>
<SENT sid="4" pm="."><plain>Sensorimotor function was evaluated 1-28 days after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> and cognitive function was determined 30-35 days after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Thereafter, <z:mpath ids='MPATH_124'>infarct</z:mpath> volume, neuron density, <z:mp ids='MP_0003354'>astrogliosis</z:mp>, and 5-LOX expression in the brain were determined </plain></SENT>
<SENT sid="6" pm="."><plain>KEY FINDINGS: <z:chebi fb="1" ids="50694">Minocycline</z:chebi> accelerated the recovery of sensorimotor and cognitive functions, attenuated the loss of neuron density, and inhibited <z:mp ids='MP_0003354'>astrogliosis</z:mp> in the boundary zone around the ischemic core, but did not affect <z:mpath ids='MPATH_124'>infarct</z:mpath> volume </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="1" ids="50694">Minocycline</z:chebi> significantly inhibited the increased 5-LOX expression in the proliferated astrocytes in the boundary zone, and in the macrophages/microglia in the ischemic core </plain></SENT>
<SENT sid="8" pm="."><plain>SIGNIFICANCE: <z:chebi fb="1" ids="50694">Minocycline</z:chebi> accelerates functional recovery in the <z:hpo ids='HP_0011010'>chronic</z:hpo> phase of focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>, which may be partly associated with the reduction of 5-LOX expression </plain></SENT>
</text></document>